A detailed history of Wells Fargo & Company transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 64,783 shares of DNLI stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,783
Previous 66,365 2.38%
Holding current value
$1.37 Million
Previous $1.42 Million 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$15.83 - $23.35 $25,043 - $36,939
-1,582 Reduced 2.38%
64,783 $1.33 Million
Q4 2023

Feb 09, 2024

SELL
$16.2 - $23.18 $1.13 Million - $1.61 Million
-69,561 Reduced 51.18%
66,365 $1.42 Million
Q3 2023

Nov 13, 2023

SELL
$20.63 - $30.17 $549,335 - $803,366
-26,628 Reduced 16.38%
135,926 $2.8 Million
Q2 2023

Aug 15, 2023

BUY
$23.37 - $32.96 $876,001 - $1.24 Million
37,484 Added 29.97%
162,554 $4.8 Million
Q1 2023

May 12, 2023

BUY
$21.91 - $32.67 $1.32 Million - $1.97 Million
60,381 Added 93.34%
125,070 $2.88 Million
Q4 2022

Feb 13, 2023

SELL
$26.28 - $33.92 $5,203 - $6,716
-198 Reduced 0.31%
64,689 $1.8 Million
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $112,164 - $166,411
-4,319 Reduced 6.24%
64,887 $1.99 Million
Q2 2022

Aug 12, 2022

SELL
$20.88 - $35.19 $857,374 - $1.44 Million
-41,062 Reduced 37.24%
69,206 $2.04 Million
Q1 2022

May 16, 2022

SELL
$29.0 - $47.27 $964,772 - $1.57 Million
-33,268 Reduced 23.18%
110,268 $3.55 Million
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $903,291 - $1.17 Million
-21,209 Reduced 12.87%
143,536 $6.4 Million
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $822,802 - $1.33 Million
16,972 Added 11.49%
164,745 $8.31 Million
Q2 2021

Aug 16, 2021

BUY
$50.3 - $78.44 $1.59 Million - $2.48 Million
31,649 Added 27.25%
147,773 $11.6 Million
Q1 2021

May 13, 2021

SELL
$53.8 - $81.53 $407,266 - $617,182
-7,570 Reduced 6.12%
116,124 $6.63 Million
Q4 2020

Feb 09, 2021

BUY
$36.89 - $93.56 $1.4 Million - $3.55 Million
37,945 Added 44.25%
123,694 $10.4 Million
Q3 2020

Nov 05, 2020

BUY
$23.13 - $38.84 $132,997 - $223,330
5,750 Added 7.19%
85,749 $3.07 Million
Q2 2020

Aug 13, 2020

SELL
$16.01 - $28.82 $1.27 Million - $2.29 Million
-79,340 Reduced 49.79%
79,999 $1.94 Million
Q1 2020

May 14, 2020

BUY
$14.2 - $27.98 $2.26 Million - $4.46 Million
159,339 New
159,339 $2.79 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.84B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.